NCT07132112View on ClinicalTrials.gov

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

Auto Immune Disease

Interventions

BIOLOGICAL

GT719 Injection

GT719 Injection

Trial Locations (1)

Unknown

Affiliated Hospital of Nantong University, Nantong

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

collaborator

Affiliated Hospital of Nantong University

OTHER

lead

Grit Biotechnology

INDUSTRY

NCT07132112 - GT719 Injection for Moderate to Severe Refractory Autoimmune Disease | Biotech Hunter | Biotech Hunter